Expertise in
10
conditions

Dr. Tien I. Su

Rheumatology
12456 Washington Blvd, 
Whittier, CA 
On Staff At
Offers Telehealth
21 Years of Experience
Expertise in
10
conditions
12456 Washington Blvd, 
Whittier, CA 

Overview

Tien Su is a Rheumatologist in Whittier, California. Dr. Su has been practicing medicine for over 21 years is highly rated in 10 conditions, according to our data. Her top areas of expertise are Rheumatoid Arthritis (RA), Postmenopausal Osteoporosis, Osteoporosis, and Fibromyalgia.

Her clinical research consists of co-authoring 1 peer reviewed article and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

University Of California-Los Angeles School Of Medicine , Medical Education , 2001 - 2005, 2005

Residency

LAC-Olive View-UCLA Medical Center , Internal Medicine , 2006 - 2008

Specialties

Rheumatology

Licenses

Internal Medicine in CA

Board Certifications

American Board Of Internal Medicine

Fellowships

Keck School of Medicine of the University of Southern California , Rheumatology , 2008 - 2010

Hospital Affiliations

Pih Health Hospital-Whittier

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Group
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Nippon Life
  • INSURANCE PLAN
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Amicus Arthritis And Osteoporosis Center Inc
12456 Washington Blvd, Whittier, CA 90602

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Vagus Nerve Stimulation Using the SetPoint System for Moderate to Severe Rheumatoid Arthritis: The RESET-RA Study
Vagus Nerve Stimulation Using the SetPoint System for Moderate to Severe Rheumatoid Arthritis: The RESET-RA Study
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Procedure, Device, Drug
Study Drug: Conventional Synthetic DMARD
Study Phase: Phase 3
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 17, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Enrollment Status: Completed
Publish Date: March 27, 2024
Intervention Type: Biological, Drug
Study Drugs: GSK3196165, Tofacitinib, Methotrexate, Folic acid
Study Phase: Phase 3
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: February 07, 2024
Intervention Type: Drug, Biological
Study Drugs: Otilimab, csDMARD
Study Phase: Phase 3
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
Enrollment Status: Completed
Publish Date: July 17, 2023
Intervention Type: Drug, Biological
Study Drugs: GSK3196165, Sarilumab, csDMARDs
Study Phase: Phase 3
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 9 Less Clinical Trials

1 Total Publications

Systemic lupus erythematosus coronary vasculitis demonstrated on cardiac computed tomography.
Systemic lupus erythematosus coronary vasculitis demonstrated on cardiac computed tomography.
Journal: Current problems in diagnostic radiology
Published: May 15, 2014
Similar Doctors
Expertise in
22
conditions
Dr. Daniel J. Wallace
Rheumatology
Expertise in
22
conditions
Dr. Daniel J. Wallace
Rheumatology
8730 Alden Dr, 
Los Angeles, CA 
 (20.6 miles away)
310-423-3870
Languages Spoken:
English
See accepted insurances

Daniel Wallace is a Rheumatologist in Los Angeles, California. Dr. Wallace is highly rated in 22 conditions, according to our data. His top areas of expertise are Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Sjogren Syndrome, and Rheumatoid Arthritis (RA).

Expertise in
21
conditions
Dr. Tanaz A. Kermani
Rheumatology
Expertise in
21
conditions
Dr. Tanaz A. Kermani
Rheumatology
2020 Santa Monica Boulevard, Suite 540, 
Santa Monica, CA 
 (25.2 miles away)
310-582-6350
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tanaz Kermani is a Rheumatologist in Santa Monica, California. Dr. Kermani is highly rated in 21 conditions, according to our data. Her top areas of expertise are Temporal Arteritis, Giant Cell Arteritis (GCA), Vasculitis, and Takayasu Arteritis. Dr. Kermani is currently accepting new patients.

Expertise in
12
conditions
Dr. Daniel Furst
Rheumatology
Expertise in
12
conditions
Dr. Daniel Furst
Rheumatology

Pacific Arthritis Care Center Inc.

5230 Pacific Concourse Dr Ste 100, 
Los Angeles, CA 
 (21.3 miles away)
310-297-9221
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Furst is a Rheumatologist in Los Angeles, California. Dr. Furst is highly rated in 12 conditions, according to our data. His top areas of expertise are Systemic Sclerosis (SSc), Scleroderma, Rheumatoid Arthritis (RA), and Arthritis.

Frequently Asked Questions about Dr. Tien I. Su

How do I make an appointment with Dr. Tien I. Su?

You can book an appointment with Dr. Tien I. Su by calling their office at 562-758-6600. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Tien I. Su a top-rated expert for Rheumatoid Arthritis (RA)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Tien I. Su is classified as an Distinguished expert for Rheumatoid Arthritis (RA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Tien I. Su specialize in?

While Dr. Tien I. Su is a Rheumatology, they have specific expertise in Rheumatoid Arthritis (RA), Postmenopausal Osteoporosis, and Osteoporosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Tien I. Su participate in research or clinical trials?

Yes. Dr. Tien I. Su has published 1 articles and abstracts on conditions like Rheumatoid Arthritis (RA). You can view a list of Dr. Tien I. Su's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Tien I. Su accept my insurance?

Dr. Tien I. Su accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 562-758-6600 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Su's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 36 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile